β-PGG exhibits potent anti-HCC activity by modulating PCID2 expression, PI3K/Akt signaling, and cell cycle regulation, and it represents a promising lead compound with PCID2-targeting potential. This evidence concerns the gene AKT1 and hepatocellular carcinoma.